Total amount raised
$295 Millions
Latest funding date
10/01/2021
Location
Immunai has successfully raised funds through multiple rounds, with its latest being a Series B round closed on October 27, 2021. The company has garnered support from 14 investors, including Piedmont Capital Investments and Alexandria Venture Investments.
Immunai's innovative approach to mapping and reprogramming immunology using machine learning has attracted significant interest from the biotech community. Keep reading to explore the intricacies of Immunai's fundraising journey and the investors backing this pioneering platform.
What Is Immunai?
Immunai, founded in December 2018, is a biotechnology company headquartered in New York, with additional locations in San Francisco and Tel Aviv. The company was established by Ansuman Satpathy, Dan Littman, Danny Wells, Luis F Voloch, and Noam Solomon.
Operating in the fields of analytics, artificial intelligence, biotechnology, machine learning, and therapeutics, Immunai employs between 101 and 250 people. The company focuses on mapping the immune system using single-cell genomics and machine learning to advance immune-related therapeutics.
How Much Funding Has Immunai Raised?
- Seed Round
- Amount Raised: $20M
- Date: May 2020
- Lead Investors: TLV Partners, Viola Group
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To build an AI map of the immune system and support initial operations and research.
- Series A
- Amount Raised: $60M
- Date: February 2021
- Lead Investors: Catalio Capital Management, Charles and Lynn Schusterman Family Philanthropies, Dexcel Pharma, Duquesne Family Office
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support ongoing operations and acquisitions.
- Series B
- Amount Raised: $215M
- Date: October 2021
- Lead Investors: Koch Disruptive Technologies
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand Immunai’s “drug actuary” platform for target validation and evaluation.
Total amount raised: $295M. Current valuation: Not publicly disclosed.
Key Investors
- Koch Disruptive Technologies
- Details: A subsidiary of Koch Industries focused on investing in high-growth companies. They aim to support transformative technologies that can disrupt industries.
- Investment Focus Areas: Technology, healthcare, industrials, energy.
- Notable Investments: Desktop Metal, INSIGHTEC, Kinsa.
- Catalio Capital Management
- Details: A firm that focuses on life sciences and healthcare investments. They provide capital to companies that are at the forefront of medical innovation.
- Investment Focus Areas: Life sciences, healthcare.
- Notable Investments: Information not provided.
- Charles and Lynn Schusterman Family Philanthropies
- Details: A philanthropic organization that supports various causes, including healthcare, education, and community services. They aim to create a positive impact through strategic investments.
- Investment Focus Areas: Healthcare, education, community services.
- Notable Investments: Various philanthropic initiatives in healthcare and education.
- Dexcel Pharma
- Details: A pharmaceutical company involved in the development and manufacturing of medications. They focus on creating high-quality generic and specialty medications.
- Investment Focus Areas: Pharmaceutical development, manufacturing.
- Notable Investments: Development and manufacturing of generic and specialty medications.
- Duquesne Family Office
- Details: The family office of Stanley Druckenmiller, focusing on various investment opportunities. They manage a diverse portfolio across multiple sectors.
- Investment Focus Areas: Technology, healthcare, diverse investment opportunities.
- Notable Investments: Investments in technology and healthcare sectors.
What's Next for Immunai?
Immunai stands at the cusp of significant growth, driven by its innovative "drug actuary" platform and the Annotated Multiomic Immune Cell Atlas (AMICA). With over 30 partnerships with leading pharmaceutical companies and academic institutions, the company is poised to leverage its proprietary technologies to develop novel immune medicines. The recent $215 million Series B funding round underscores the vast opportunities available, including expanding their platform for target validation and evaluation.
Future fundraising opportunities appear promising as Immunai continues to demonstrate progress in immune system mapping and therapeutic development. The company's rapid growth and strategic acquisitions, such as Nebion, suggest potential for additional funding rounds and possibly an IPO. However, challenges remain, including the complexity of integrating advanced technologies and maintaining competitive edge in a crowded biotech landscape.
Use Clay to Get Funding Data
Sales professionals, take advantage of Clay’s platform to access comprehensive fundraising data on companies like Immunai and gather other critical business insights. Sign up for free and start leveraging these powerful tools today.
